The bradykinin-forming cascade and its role in hereditary angioedema

Annals of Allergy, Asthma and Immunology

Volumn 104, Issue 3, 2010, Pages 193-204

  Kaplan, Allen P ^a   Joseph, Kusumam ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; BETA 2 ADRENERGIC RECEPTOR; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 12A; BRADYKININ; COMPLEMENT COMPONENT C1S INHIBITOR; CYTOKERATIN 1; DANAZOL; ECALLANTIDE; FRESH FROZEN PLASMA; HEAT SHOCK PROTEIN 90; HIGH MOLECULAR WEIGHT KININOGEN; ICATIBANT; KALLIKREIN; KALLIKREIN INHIBITOR; KININ; LIGAND; NITRIC OXIDE; PLASMA KALLIKREIN; PLASMIN; PLASMINOGEN; PREKALLIKREIN; PROLINE CARBOXYPEPTIDASE; PROSTACYCLIN; STANOZOLOL; TRANEXAMIC ACID; UROKINASE RECEPTOR;

ANGIONEUROTIC EDEMA; CELL ACTIVATION; CELL MEMBRANE; CELL SURFACE; DISEASE CLASSIFICATION; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME REGULATION; ENZYME RELEASE; FIBRINOLYSIS; GENE MUTATION; HUMAN; IMMUNOPATHOGENESIS; IMMUNOPROPHYLAXIS; KALLIKREIN KININ SYSTEM; MUSCLE CRAMP; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN DEFICIENCY; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; PROTEIN SYNTHESIS; PROTEINASE INHIBITION; REACTOR CASCADE; REVIEW;

ANDROGENS; ANGIOEDEMAS, HEREDITARY; BRADYKININ; COMPLEMENT C1 INACTIVATOR PROTEINS; COMPLEMENT INACTIVATING AGENTS; ENDOTHELIAL CELLS; FACTOR XII; HSP90 HEAT-SHOCK PROTEINS; HUMANS; KALLIKREINS; KININOGEN, HIGH-MOLECULAR-WEIGHT; PLASMA KALLIKREIN; PREKALLIKREIN; RECEPTOR, BRADYKININ B2;

EID: 77649144033     PISSN: 10811206     EISSN: 15344436     Source Type: Journal    
DOI: 10.1016/j.anai.2010.01.007     Document Type: Review

References (103)

1. Donaldson V., and Evans R. A biochemical abnormality in hereditary angioneurotic edema. Am J Med 35 (1963) 37-44
2. Davis III A.E. C1 inhibitor and hereditary angioneurotic edema. Annu Rev Immunol 6 (1988) 595-628
3. Bock S., Skriver K., Nielsen E., et al. Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization. Biochemistry 25 (1986) 4292-4301
4. Pappalardo E., Cicardi M., Duponchel C., et al. Frequent de novo mutations and exon deletions in the C1 inhibitor gene of patients with angioedema. J Allergy Clin Immunol 106 (2000) 1147-1154
5. Frank M., Gelfand J., and Atkinson J. Hereditary angioedema: the clinical syndrome and its management. Ann Intern Med 84 (1976) 580-593
6. Zuraw B. Clinical practice: hereditary angioedema. N Engl J Med 359 (2008) 1027-1036
7. Sheffer A., Craig J., Willms-Kretschmer K., et al. Histopathological and ultrastructural observations on tissues from patients with hereditary angioneurotic edema. J Allergy 47 (1971) 292-297
8. Shah T., Knowles W., and McGeady S. Hereditary angioedema with recurrent abdominal pain and ascites. J Allergy Clin Immunol 96 (1995) 259-261
9. Agostoni A., Aygoren-Pursun E., Binkley K., et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 114 (2004) S51-S131
10. Frank M. Hereditary angioedema: the clinical syndrome and its management in the United States. Immunol Allergy Clin North Am 26 (2006) 653-668
11. Rosen F., Alper C., Pensky J., et al. Genetically determined heterogeneity of the C1 esterase inhibitor in patients with hereditary angioneurotic edema. J Clin Invest 50 (1971) 2143-2149
12. Tosi M. Molecular genetics of C1 inhibitor. Immunobiology 119 (1998) 358-365
13. Cicardi M., Igarashi T., Rosen F., et al. Molecular basis for the deficiency of complement 1 inhibitor in type I hereditary angioneurotic edema. J Clin Invest 79 (1987) 698-702
14. Ernst S., Circolo A., Davis A., et al. Impaired production of both normal and mutant C1 inhibitor proteins in type I hereditary angioedema with a duplication in exon 8. J Immunol 157 (1996) 405-410
15. Zuraw B., and Herschbach J. Detection of C1 inhibitor mutations in patients with hereditary angioedema. J Allergy Clin Immunol 105 (2000) 541-546
16. Tosi M. Structural and functional aspects of C1-inhibitor at the gene and protein level. Immunobiology 199 (1998) 358-365
17. Skriver K., Radziejewska E., Silbermann J., et al. CpG mutations in the reactive site of human C1 inhibitor. J Biol Chem 264 (1989) 3066-3071
18. Bork K., Barnstedt S., Koch P., et al. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 356 (2000) 213-217
19. Bork K., Gul D., Hardt J., et al. Hereditary angioedema with normal C1 inhibitor: clinical symptoms and course. Am J Med 120 (2006) 987-992
20. Cichon S., Martin L., Hennies H., et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 79 (2006) 1098-1104
21. Gordon E.M., Ratnoff O.D., Saito H., et al. Rapid fibrinolysis, augmented Hageman factor (factor XII) titers, and decreased C1 esterase inhibitor titers in women taking oral contraceptives. J Lab Clin Med 96 (1980) 762-769
22. Blanch A., Roche O., Urrutia I., et al. First case of homozygous C1 inhibitor deficiency. J Allergy Clin Immunol 118 (2006) 1330-1335
23. Patston P., Gettins P., Beechem J., et al. Mechanism of serpin action: evidence that C1 inhibitor functions as a suicide substrate. Biochemistry 30 (1991) 8876-8882
24. Kramer J., Rosen F., Colten H., et al. Transinhibition of C1 inhibitor synthesis in type I hereditary angioneurotic edema. J Clin Immunol 91 (1993) 1258-1262
25. Silverberg M., and Kaplan A.P. Enzymatic activities of activated and zymogen forms of human Hageman factor (factor XII). Blood 60 (1982) 64-70
26. Silverberg M., Dunn J., Garen L., et al. Autoactivation of human Hageman factor: demonstration utilizing a synthetic substrate. J Biol Chem 255 (1980) 7281-7286
27. Cochrane C.G., Revak S.D., and Wuepper K.D. Activation of Hageman factor in solid and fluid phases: a critical role of kallikrein. J Exp Med 138 (1973) 1564-1583
28. Dunn J.T., Silverberg M., and Kaplan A.P. The cleavage and formation of activated human Hageman factor by autodigestion and by kallikrein. J Biol Chem 257 (1982) 1779-1784
29. Dunn J.T., and Kaplan A.P. Formation and structure of human Hageman factor fragments. J Clin Invest 70 (1982) 627-631
30. Ghebrehiwet B., Randazzo B., Dunn J., et al. Mechanisms of activation of the classical pathway of complement by Hageman factor fragment. J Clin Invest 71 (1983) 1450-1456
31. Mandle R., Colman R., and Kaplan A. Identification of prekallikrein and high-molecular-weight kininogen as a complex in human plasma. Proc Natl Acad Sci U S A 73 (1976) 4179-4183
32. Joseph K., Tholanikunnel B., and Kaplan A. Factor XII-independent cleavage of high molecular weight kininogen by prekallikrein and inhibition by C1 inhibitor. J Allergy Clin Immunol 124 (2009) 143-149
33. Mandle R.J., and Kaplan A. Hageman factor substrates: human plasma prekallikrein: mechanism of activation by Hageman factor and participation in Hageman factor-dependent fibrinolysis. J Biol Chem 252 (1977) 6097-6104
34. Reddigari S., and Kaplan A.P. Cleavage of human high-molecular weight kininogen by purified kallikreins and upon contact activation of plasma. Blood 71 (1988) 1334-1340
35. Tait J.F., and Fujikawa K. Primary structure requirements for the binding of human high molecular weight kininogen to plasma prekallikrein and factor XI. J Biol Chem 262 (1987) 11651-11656
36. Kellermann J., Lottspeich F., Henschen A., et al. Completion of the primary structure of human high-molecular-mass kininogen: the amino acid sequence of the entire heavy chain and evidence for its evolution by gene triplication. Eur J Biochem 154 (1986) 471-478
37. Higashiyama S., Ohkubo I., Ishiguro H., et al. Human high molecular weight kininogen as a thiol proteinase inhibitor: presence of the entire inhibition capacity in the native form of heavy chain. Biochemistry 25 (1986) 1669-1675
38. Ishiguro H., Higashiyama S., Ohkubo I., et al. Mapping of functional domains of human high molecular weight and low molecular weight kininogens using murine monoclonal antibodies. Biochemistry 26 (1987) 7021-7029
39. Griffin J.H. Role of surface in surface-dependent activation of Hageman factor (blood coagulation factor XII). Proc Natl Acad Sci U S A 75 (1978) 1998-2002
40. Weiss R., Silverberg M., and Kaplan A.P. The effect of C1 inhibitor upon Hageman factor autoactivation. Blood 68 (1986) 239-243
41. Tankersley D.L., and Finlayson J.S. Kinetics of activation and autoactivation of human factor XII. Biochemistry 23 (1984) 273-279
42. Griffin J.H., and Cochrane C.G. Mechanisms for the involvement of high molecular weight kininogen in surface-dependent reactions of Hageman factor. Proc Natl Acad Sci U S A 73 (1976) 2554-2558
43. Wiggins R.C., Bouma B.N., Cochrane C.G., et al. Role of high-molecular-weight kininogen in surface-binding and activation of coagulation Factor XI and prekallikrein. Proc Natl Acad Sci U S A 74 (1977) 4636-4640
44. Silverberg M., Nicoll J., and Kaplan A. The mechanism by which the light chain of cleaved HMW-kininogen augments the activation of prekallikrein, factor XI and Hageman factor. Thromb Res 20 (1980) 173-189
45. Gigli I., Mason J.W., Colman R.W., et al. Interaction of plasma kallikrein with the C1 inhibitor. J Immunol 104 (1970) 574-581
46. Schreiber A., Kaplan A., and Austen K. Inhibition by C1INH of Hagemann factor fragment activation of coagulation, fibrinolysis, and kinin generation. J Clin Invest 52 (1973) 1402-1409
47. Ziccardi R.J. Spontaneous activation of the first component of human complement (C1) by an intramolecular autocatalytic mechanism. J Immunol 128 (1982) 2500-2504
48. Cugno M., Nuijens J., Hack E., et al. Plasma levels of C1-inhibitor complexes and cleaved C1-inhibitor in patients with hereditary angioneurotic edema. J Clin Invest 85 (1990) 1215-1220
49. Landerman N., Webster M., Becker E., et al. Hereditary angioneurotic edema, II: deficiency of inhibitor for serum globulin permeability factor and/or plasma kallikrein. J Allergy 33 (1962) 330-341
50. Kaplan A.P., and Austen K.F. A pre-albumin activator of prekallikrein. J Immunol 105 (1970) 802-811
51. Donaldson V.H., Rosen F.S., and Bing D.H. Role of the second component of complement (C2) and plasmin in kinin release in hereditary angioneurotic edema (H.A.N.E.) plasma. Trans Assoc Am Phys 90 (1977) 174-183
52. Klemperer M.R., Donaldson V.H., and Rosen F.S. Effect of C'1 esterase on vascular permeability in man: studies in normal and complement-deficient individuals and in patients with hereditary angioneurotic edema. J Clin Invest 47 (1968) 604-611
53. Strang C., Auerbach H., and Rosen F. C1s-induced vascular permeability in C2-deficient guinea pigs. J Immunol 137 (1986) 631-635
54. Donaldson V.H. Mechanisms of activation of C'1 esterase in hereditary angioneurotic edema plasma in vitro. J Exp Med 127 (1968) 411-429
55. Curd J., Prograis L.J., and Cochrane C. Detection of active kallikrein in induced blister fluids of hereditary angioedema patients. N Engl J Med 152 (1980) 742-747
56. Fields T., Ghebrehiwet B., and Kaplan A.P. Kinin formation in hereditary angioedema plasma: evidence against kinin derivation from C2 and in support of "spontaneous" formation of bradykinin. J Allergy Clin Immunol 72 (1983) 54-60
57. Smith M., and Kerr M. Cleavage of the second component of complement by plasma proteases: implications in hereditary C1-inhibitor deficiency. Immunology 56 (1985) 561-570
58. Shoemaker L., Schurman S., Donaldson V., et al. Hereditary angioneurotic oedema: characterization of plasma kinin and vascular permeability-enhancing activities. Clin Exp Immunol 95 (1994) 22-28
59. Schapira M., Silver L., Scott C., et al. Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema. N Engl J Med 308 (1983) 1050-1053
60. Cugno M., Cicardi M., Coppola R., et al. Activation of factor XII and cleavage of high molecular weight kininogen during acute attacks in hereditary and acquired C1-inhibitor deficiencies. Immunopharmacology 33 (1996) 361-364
61. Nussberger J., Cugno M., Cicardi M., et al. Local bradykinin generation in hereditary angioedema. J Allergy Clin Immunol 104 (1999) 1321-1322
62. Han E., MacFarlane R., Mulligan A., et al. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest 8 (2002) 1057-1063
63. Zahedi R., Bissler J., Davis III A.E., Andreadis C., and Wisnieski J.J. Unique C1 inhibitor dysfunction in a kindred without angioedema, II: identification of an Ala443→Val substitution and functional analysis of the recombinant mutant protein. J Clin Invest 95 (1995) 1299-1305
64. Schmaier A.H., Kuo A., Lundberg D., et al. The expression of high molecular weight kininogen on human umbilical vein endothelial cells. J Biol Chem 263 (1988) 16327-16333
65. Reddigari S.R., Shibayama Y., Brunnee T., et al. Human Hageman factor (factor XII) and high molecular weight kininogen compete for the same binding site on human umbilical vein endothelial cells. J Biol Chem 268 (1993) 11982-11987
66. Joseph K., Ghebrehiwet B., Peerschke E.I., et al. Identification of the zinc-dependent endothelial cell binding protein for high molecular weight kininogen and factor XII: identity with the receptor that binds to the globular "heads" of C1q (gC1q-R). Proc Natl Acad Sci U S A 93 (1996) 8552-8557
67. Colman R.W., Pixley R.A., Najamunnisa S., et al. Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor. J Clin Invest 100 (1997) 1481-1487
68. Mahdi F., Madar Z.S., Figueroa C.D., et al. Factor XII interacts with the multiprotein assembly of urokinase plasminogen activator receptor, gC1qR, and cytokeratin 1 on endothelial cell membranes. Blood 99 (2002) 3585-3596
69. Hasan A.A., Zisman T., and Schmaier A.H. Identification of cytokeratin 1 as a binding protein and presentation receptor for kininogens on endothelial cells. Proc Natl Acad Sci U S A 95 (1998) 3615-3620
70. Joseph K., Ghebrehiwet B., and Kaplan A.P. Cytokeratin 1 and gC1qR mediate high molecular weight kininogen binding to endothelial cells. Clin Immunol 92 (1999) 246-255
71. Reddigari S.R., Kuna P., Miragliotta G., et al. Human high molecular weight kininogen binds to human umbilical vein endothelial cells via its heavy and light chains. Blood 81 (1993) 1306-1311
72. Shariat-Madar Z., Mahdi F., and Schmaier A.H. Mapping binding domains of kininogens on endothelial cell cytokeratin 1. J Biol Chem 274 (1999) 7137-7145
73. Joseph K., Tholanikunnel B.G., Ghebrehiwet B., et al. Interaction of high molecular weight kininogen binding proteins on endothelial cells. Thromb Haemost 91 (2004) 61-70
74. Fernando L.P., Natesan S., Joseph K., and Kaplan A.P. High molecular weight kininogen and factor XII binding to endothelial cells and astrocytes. Thromb Haemost 90 (2003) 787-795
75. Fernando A., Fernando L., Fukuda Y., et al. Assembly, activation, and signaling by kinin-forming proteins on human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 289 (2005) H251-H257
76. Zhao Y., Qiu Q., Mahdi F., et al. Assembly and activation of HK-PK complex on endothelial cells results in bradykinin liberation and NO formation. Am J Physiol Heart Circ Physiol 280 (2001) H1821-H1829
77. Joseph K., Tholanikunnel B., and Kaplan A. Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of factor XII. Proc Natl Acad Sci U S A 99 (2002) 896-900
78. Shariat-Madar Z., Mahdi F., and Schmaier A. Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J Biol Chem 277 (2002) 17962-17969
79. Joseph K., Shibayama Y., Ghebrehiwet B., et al. Factor XII-dependent contact activation on endothelial cells and binding proteins gC1qR and cytokeratin 1. Thromb Haemost 85 (2001) 119-124
80. Joseph K., Ghebrehiwet B., and Kaplan A.P. Activation of the kinin-forming cascade on the surface of endothelial cells. Biol Chem 382 (2001) 71-75
81. Motta G., Rojkjaer R., Hasan A.A., et al. High molecular weight kininogen regulates prekallikrein assembly and activation on endothelial cells: a novel mechanism for contact activation. Blood 91 (1998) 516-528
82. Joseph K., Tuscano T., and Kaplan A. Studies of the mechanism of bradykinin formation in hereditary angioedema plasma. Ann Allergy Asthma Immunol 101 (2008) 279-286
83. Cochrane C.G., and Revak S.D. Dissemination of contact activation in plasma by plasma kallikrein. J Exp Med 152 (1980) 608-619
84. Frank M., Sergent J., Kane M., et al. Epsilon aminocaproic acid therapy of hereditary angioneurotic edema: a double-blind study. N Engl J Med 286 (1972) 808-812
85. Sheffer A., Austen K., and Rosen F. Tranexamic acid therapy in hereditary angioneurotic edema. N Engl J Med 287 (1972) 452-454
86. Wallace E.M., Perkins S.J., Sim R.B., et al. Degradation of C1-inhibitor by plasmin: implications for the control of inflammatory processes. Mol Med 3 (1997) 385-396
87. Kaplan A.P., and Austen K.F. A prealbumin activator of prekallikrein, II: derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin. J Exp Med 133 (1971) 696-712
88. Cugno M., Hack C.E., de Boer J.P., et al. Generation of plasmin during acute attacks of hereditary angioedema. J Lab Clin Med 121 (1993) 38-43
89. Zuraw B. Current and future therapy for hereditary angioedema. Clin Immunol 114 (2005) 10-16
90. Prematta M., Gibbs J., Pratt E., et al. Fresh frozen plasma for the treatment of hereditary angioedema. Ann Allergy Asthma Immunol 98 (2007) 383-388
91. Gelfand J.A., Sherins R.J., Alling D.W., et al. Treatment of hereditary angioedema with danazol: reversal of clinical and biochemical abnormalities. N Engl J Med 295 (1976) 1444-1448
92. Sloane D., Lee C., and Sheffer A. Hereditary angioedema: safety of long-term stanozolol therapy. J Allergy Clin Immunol 120 (2007) 654-658
93. Cicardi M., Castelli R., Zingale L., et al. Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients. J Allergy Clin Immunol 99 (1997) 194-196
94. Gompels M.M., Lock R.J., Abinun M., et al. C1 inhibitor deficiency: consensus document. Clin Exp Immunol 139 (2005) 379-394
95. Farkas H., Jakab L., Temesszentandrasi G., et al. Hereditary angioedema: a decade of human C1-inhibitor concentrate therapy. J Allergy Clin Immunol 120 (2007) 941-947
96. Frank M. Hereditary angioedema: a half century of progress. J Allergy Clin Immunol 114 (2004) 626-628
97. Joseph K., Tholanikunnel T., and Kaplan A. Infusion of C1 inhibitor as therapy for swelling in hereditary angioedema patients reverses abnormalities of the plasma bradykinin-forming pathways and fibrinolysis. [abstract]. J Allergy Clin Immunol 123 (2009) S102
98. Cinryze™ Prescribing Information (2009), ViroPharma Inc, Exton, PA
99. Berinert prescribing information. http://www.berinert.com/prescribing-information.aspx
100. Levy R., McNeil D., Li H., et al. Results of a phase 3 double-blind placebo-controlled trial, edema 3: a study of subcutaneous DX-88 (ecallantide) in patients with hereditary angioedema. [abstract]. Ann Allergy Asthma Immunol 100 (2008) A6
101. Schneider L., Lumry W., Vegh A., et al. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor. J Allergy Clin Immunol 120 (2007) 416-422
102. Zingale L., Zanichelli P., Deliliers D., et al. Anaphylaxis in response to C1 esterase inhibitor in a patient with hereditary angioedema: successful treatment with DX088, a human plasma kallikrein inhibitor. Allergy Clin Immunol Int 19 (2007) 159-163
103. Bork K., Frank J., Grundt B., et al. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J Allergy Clin Immunol 119 (2007) 1497-1503